Sage Journals: Discover world-class research

Abstract

Background:

A low vitamin D status has been associated with multiple sclerosis (MS). Most circulating vitamin D metabolites are bound to vitamin D binding protein (DBP).

Objectives:

The purpose of this study was to explore whether there is an association between MS and DBP.

Methods:

We compared DBP concentrations in blood samples of controls (n = 30) and subjects with relapsing–remitting MS (RRMS) during remission (n = 29) and relapse (n = 15). Furthermore, we explored correlations of DBP with 25- hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D levels (1,25(OH)₂D), and the effect of high-dose vitamin D₃ supplementation on DBP levels in RRMS patients (n = 15).

Results:

DBP-concentration did not differ between the sub-groups measured, and there was no correlation between DBP and vitamin D metabolite concentration within the physiological range. Upon supplementation of high doses vitamin D₃, DBP concentration remained unaltered. After supplementation, serum 1,25(OH)₂D(R = 0.517, p = 0.049), but not 25(OH)D, correlated positively with DBP.

Conclusions:

We found no association between DBP, MS, and vitamin D status within the physiological range. After high - dose vitamin D supplementation, DBP concentrations may be relevant for vitamin D metabolism.

Keywords

Multiple sclerosis vitamin D vitamin D binding protein

Get full access to this article

View all access options for this article.

References

Munger

Levin

Hollis

. Serum 25 - hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296: 2832–2838.

Sawcer

Hellenthal

Pirinen

. Genetic risk and a primary role for cell - mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214–219.

Simpson

Taylor

Blizzard

. Higher 25 - hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010; 68: 193–203

Mowry

Waubant

McCulloch

. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012; 72: 234–240.

Van der Mei

Ponsonby

Dwyer

. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 2007; 254: 581–590.

Knippenberg

Bol

Damoiseaux

. A poor vitamin D status in patients with MS is negatively correlated with depression, but not with fatigue. Acta Neurol Scand 2011; 124: 171–175.

White

Cooke

. The multifunctional properties and characteristics of vitamin D - binding protein. Trends Endocrinol Metab 2000; 8: 320–327.

Kew

Webster

. Gc - globulin (vitamin D - binding protein) enhances the neutrophil chemotactic activity of C5a and C5a des Arg. J Clin Invest 1988; 82: 364–369.

Yamamoto

Kumashiro

. Conversion of vitamin D3 binding protein (group - specific component) to a macrophage activating factor by the stepwise action of beta - galactosidase of B cells and sialidase of T cells. J Immunol 1993; 151: 2794–2802.

10.

Disanto

Ramagopalan

Para

. The emerging role of vitamin D binding protein in multiple sclerosis. J Neurol. 2011; 258: 353–358.

11.

Ottervald

Franzen

Nilsson

. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. J Proteomics 2010; 73:1117–1132.

12.

Stoop

Singh

Dekker

. Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis. PLoS One 2010; 5(8): e12442.

13.

Qin

Liu

. Alteration of DBP levels in CSF of patients with MS by proteomics analysis. Cell Mol Neurobiol 2009; 29: 203–210.

14.

Lehmensiek

Sussmuth

Tauscher

. Cerebrospinal fluid proteome profile in multiple sclerosis. Mult Scler 2007; 13: 840–849.

15.

Smolders

Schuurman

van Strien

. Expression of vitamin D receptor and metabolizing enzymes in multiple sclerosis - affected brain tissue. J Neuropathol Exp Neurol 2013; 72: 91–105.

16.

Polman

Reingold

Edan

. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol 2005; 58: 840–846.

17.

Knippenberg

Smolders

Thewissen

. Effect of vitamin D₃ supplementation on peripheral B cell differentiation and isotype switching in patients with multiple sclerosis. Mult Scler 2011; 17: 1418–1423.

18.

Smolders

Peelen

Thewissen

. Safety and T cell modulating effects of high dose vitamin D₃ supplementation in multiple sclerosis. PLoS One 2010; 5: e15235.

19.

Disanto

Handel

Damoiseaux

. Vitamin D supplementation and antibodies against the Epstein - Barr virus in multiple sclerosis patients. Mult Scler 2013 [Epub ahead of print: 10.1177/1352458513494494].

20.

Rithidech

Honikel

Milazzo

. Protein expression profiles in pediatric multiple sclerosis: Potential biomarkers. Mult Scler 2009; 15: 455–464.

21.

Kułakowska

Ciccarelli

Wen

. Hypogelsolinemia, a disorder of the extracellular actin scavenger system, in patients with multiple sclerosis. BMC Neurol 2010; 10: 107.

22.

Niino

Fukazawa

Yabe

. Vitamin D receptor gene polymorphism in multiple sclerosis and the association with HLA class II alleles. J Neurol Sci 2000; 177: 65–71.

23.

Steckley

Dyment

Sadovnick

. Genetic analysis of vitamin D related genes in Canadian multiple sclerosis patients. Canadian Collaborative Study Group. Neurology 2000; 54: 729–732.

24.

Mendel

. The free hormone hypothesis: A physiologically based mathematical model. Endocr Rev 1989; 10: 232–274.

Circulating vitamin D binding protein levels are not associated with relapses or with vitamin D status in multiple sclerosis

Abstract

Background:

Objectives:

Methods:

Results:

Conclusions:

Keywords

Get full access to this article

References